Important Information for Actinium Pharmaceuticals, Inc. Securities Holders
New York, April 14, 2025. Rosen Law Firm, a leading global investor rights law firm, reminds purchasers of securities of Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) between October 31, 2022, and August 2, 2024 (the “Class Period”), of the significant May 26, 2025, lead plaintiff deadline.
What Happened
Actinium Pharmaceuticals is a clinical-stage biopharmaceutical company developing innovative therapies for cancer patients. During the Class Period, Actinium made several positive announcements regarding its pipeline, including the initiation of a Phase 3 study for its lead product, I-131 Apastin. However, on August 3, 2024, Actinium announced that the U.S. Food and Drug Administration (FDA) had placed a clinical hold on the Phase 3 study due to safety concerns. Following this news, the price of Actinium securities significantly declined.
Who is Eligible
If you purchased Actinium securities during the Class Period, you may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action lawsuit to recover damages for investors.
Next Steps for Investors
- If you purchased Actinium securities during the Class Period, you may be entitled to compensation.
- No out-of-pocket costs or fees are required to participate.
- To join the class action, you must submit your information at gschenker@rosenlegal.com or call Phillip Kim, Esq. toll-free at 866-767-3653 or 212-697-1001 for information on the class action.
- The deadline to request appointment as lead plaintiff is May 26, 2025.
Impact on Individual Investors
If you purchased Actinium securities during the Class Period, you may have suffered significant losses. The Rosen Law Firm is dedicated to helping investors recover their losses. By joining the class action, you may be able to hold the company accountable for misrepresentations and potentially recover your investment losses.
Global Implications
The securities class action against Actinium Pharmaceuticals has implications beyond the United States. Global investors who purchased Actinium securities during the Class Period on international exchanges may also be eligible to participate in the class action. This case highlights the importance of transparency and accurate information in the securities market, ensuring that investors make informed decisions and are not misled by companies.
Conclusion
If you purchased Actinium Pharmaceuticals securities during the Class Period, you may be entitled to compensation for your losses. The Rosen Law Firm is dedicated to helping investors recover their damages through a contingency fee arrangement. The deadline to request appointment as lead plaintiff is May 26, 2025. To join the class action, contact the Rosen Law Firm at gschenker@rosenlegal.com or call 866-767-3653 or 212-697-1001 for more information.
